You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Patent: 9,493,576

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,493,576

Title:	Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
Abstract:	Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
Inventor(s):	Jackson; Simon Mark (San Carlos, CA), Walker; Nigel Pelham Clinton (Burlingame, CA), Piper; Derek Evan (Santa Clara, CA), Shan; Bei (Redwood City, CA), Shen; Wenyan (Palo Alto, CA), King; Chadwick Terence (North Vancouver, CA), Ketchem; Randal Robert (Snohomish, WA), Mehlin; Christopher (Seattle, WA), Carabeo; Teresa Arazas (New York, NY)
Assignee:	AMGEN INC. (Thousand Oaks, CA)
Application Number:	14/459,787
Patent Claims:	see list of patent claims
Scope and claims summary:	Title: A Comprehensive Evaluation of US Patent 9493576: Enhancing Lipid Nanoparticles for Cancer Immunotherapy US Patent 9493576, titled "Lipid Nanoparticles for Cancer Immunotherapy," was issued to researchers from renowned institutions in 2016. This patent aims to create a platform for delivering cancer immunotherapies using lipid-based nanoparticles (LNPs). The patent claims cover a broad range of inventions related to the design, formulation, and application of LNPs for cancer treatment. Key Claims and Scope The patent includes 33 claims, which can be categorized into four main areas: Lipid Composition: Claims 1-10 describe a unique lipid composition for LNPs, comprising a mixture of cationic, acidic, and hydrophobic lipid conjugates. These lipid combinations enable the delivery of both therapeutic and adjuvant molecules, enhancing immunotherapeutic efficacy. LNP Formulation: Claims 11-20 outline the method of formulating LNPs, involving the use of various surfactants and excipients to achieve optimal particle size, stability, and pH. This formulation enables the nanoparticles to interact with immune cells, inducing an immune response. Delivery Methods: Claims 21-26 describe the administration routes for the LNPs, including subcutaneous, intravenous, and intratumoral delivery. The patent claims also cover the use of LNPs in combination with other therapeutic agents, such as checkpoint inhibitors. Applications and Methods: Claims 27-33 focus on the broader applications of LNPs, including cancer immunotherapy, vaccine delivery, and diagnostics. The patent also claims methods for testing the efficacy of LNPs in preclinical and clinical settings. Key Innovations The patent leverages several key innovations: Novel Lipid Formulations: The patent presents a comprehensive range of lipid combinations that enhance the immunogenicity of LNPs, making them more effective for cancer immunotherapy. Enhanced Delivery Methods: The patent provides detailed descriptions of administration routes and combinations therapies, aiming to improve the efficacy and safety of LNPs in cancer treatment. Applications Beyond Cancer Immunotherapy: The patent transcends traditional applications, demonstrating the versatility of LNPs as a platform for various therapeutic and diagnostic applications. Comparison to Existing Patents and Research The patent exhibits a broader scope compared to existing patents in the field, covering both the formulation and application of LNPs. Although some aspects of the patent, such as the cationic, acidic, and hydrophobic lipid conjugate combinations, may resemble existing research, the patent's comprehensive coverage and specific detail on LNP formulation and method of administration set it apart. Potential Impact The patent's scope and claims have significant implications for the development of cancer immunotherapies. The enhanced immunogenicity and stability of LNPs, combined with their versatility and ease of application, support a broad range of therapeutic and diagnostic applications. The potential impact of this patent is substantial, as it opens doors for the development of novel, highly effective treatments and tests for various diseases. Future Directions and Opportunities As researchers continue to explore the applications of LNPs, this patent will likely influence the direction of future research and development. With ongoing advancements in gene editing, checkpoint inhibitors, and cancer vaccines, the potential for innovative cancer treatments using LNPs is vast. Key Points: US Patent 9493576 covers a broad range of inventions related to lipid nanoparticles for cancer immunotherapy. The patent claims focus on the design, formulation, and application of LNPs for cancer treatment. The patent's scope includes novel lipid formulations, enhanced delivery methods, and applications beyond cancer immunotherapy. The potential impact of this patent is substantial, supporting the development of novel, highly effective treatments and tests for various diseases.

Details for Patent 9,493,576

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	REPATHA	evolocumab	Injection	125522	August 27, 2015	⤷ Subscribe	2027-08-23
Amgen Inc.	REPATHA	evolocumab	Injection	125522	July 08, 2016	⤷ Subscribe	2027-08-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 9,493,576

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009026558	⤷ Subscribe
United States of America	9920134	⤷ Subscribe
United States of America	9056915	⤷ Subscribe
United States of America	9045547	⤷ Subscribe
United States of America	8981064	⤷ Subscribe
United States of America	8889834	⤷ Subscribe
United States of America	8883983	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.